These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 12324574

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Usefulness of FDG-PET to detect recurrent cervical cancer based on asymptomatically elevated tumor marker serum levels--a preliminary report.
    Chang WC, Hung YC, Lin CC, Shen YY, Kao CH.
    Cancer Invest; 2004; 22(2):180-4. PubMed ID: 15199599
    [Abstract] [Full Text] [Related]

  • 3. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY, Liang JA, Chen YK, Tsai CY, Kao CH.
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [Abstract] [Full Text] [Related]

  • 4. Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker.
    Chang WC, Hung YC, Kao CH, Yen RF, Shen YY, Lin CC.
    Neoplasma; 2002; 49(5):329-33. PubMed ID: 12458332
    [Abstract] [Full Text] [Related]

  • 5. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M, Pérez-Castejón MJ, Jiménez A, Domper M, Ruiz G, Montz R, Carreras JL.
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
    Odalovic S, Stojiljkovic M, Sobic-Saranovic D, Pandurevic S, Brajkovic L, Milosevic I, Grozdic-Milojevic I, Artiko V.
    Neoplasma; 2017 Jun; 64(6):954-961. PubMed ID: 28895416
    [Abstract] [Full Text] [Related]

  • 10. [The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers].
    Xing Y, Zhao JH, Wang TS, Qiao WL, Che WJ.
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):129-33. PubMed ID: 19538891
    [Abstract] [Full Text] [Related]

  • 11. The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities.
    Filippi V, Malamitsi J, Vlachou F, Laspas F, Georgiou E, Prassopoulos V, Andreou J.
    Nucl Med Commun; 2011 Feb; 32(2):85-90. PubMed ID: 21127445
    [Abstract] [Full Text] [Related]

  • 12. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.
    Sanli Y, Kuyumcu S, Ozkan ZG, Kilic L, Balik E, Turkmen C, Has D, Isik G, Asoglu O, Kapran Y, Adalet I.
    Ann Nucl Med; 2012 Aug; 26(7):551-8. PubMed ID: 22644560
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
    Bhosale P, Peungjesada S, Wei W, Levenback CF, Schmeler K, Rohren E, Macapinlac HA, Iyer RB.
    Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
    [Abstract] [Full Text] [Related]

  • 16. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z, Szefer J, Zuchora Z, Romanowicz G, Pietrzak T.
    Pol Merkur Lekarski; 2004 Aug; 17 Suppl 1():63-6. PubMed ID: 15603351
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
    Sawicki LM, Grueneisen J, Schaarschmidt BM, Buchbender C, Nagarajah J, Umutlu L, Antoch G, Kinner S.
    Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis.
    Xiao Y, Wang L, Jiang X, She W, He L, Hu G.
    Nucl Med Commun; 2016 Nov; 37(11):1180-8. PubMed ID: 27428888
    [Abstract] [Full Text] [Related]

  • 19. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K, Hay JH, Wilson DC.
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.